Business Wire

 Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Share

Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the 48-week, Phase 2 ATLAS study of combination and monotherapy investigational treatments for advanced fibrosis (F3-F4) due to NASH. While no regimen led to a statistically significant increase in the proportion of patients who achieved the primary efficacy endpoint of a ≥1-stage improvement in fibrosis without worsening of NASH, statistically significant improvements in multiple response measures of fibrosis and liver function were observed in patients treated with a combination of the acetyl-CoA carboxylase (ACC) inhibitor firsocostat and the selective, nonsteroidal farnesoid X receptor (FXR) agonist cilofexor, compared with placebo in patients with advanced fibrosis.

The Phase 2 ATLAS study is a randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of monotherapy and dual combination regimens of cilofexor 30 mg, firsocostat 20 mg and selonsertib 18 mg in patients with advanced fibrosis (F3-F4) due to NASH. The selonsertib monotherapy treatment group was discontinued following termination of the previously reported STELLAR trials of selonsertib.

In the 392 enrolled and dosed patients, of whom 56 percent had compensated cirrhosis, a ≥1-stage improvement in fibrosis without worsening of NASH after 48 weeks of treatment was observed in the following:

Table: Week 48 Primary Endpoint - Histologic Responses*

Endpoint, n (%)

FIR
(n=33)

CILO
(n=34)

SEL/FIR
(n=71)

SEL/CILO
(n=68)

FIR/CILO
(n=67)

Placebo
(n=38)

Fibrosis improvement without NASH worsening

4 (12.1%)

p=0.94

4 (11.8%)

p=0.96

11 (15.5%)

p=0.62

13 (19.1%)

p=0.26

14 (20.9%)

p=0.17

4 (10.5%)

CILO, cilofexor (FXR agonist); FIR, firsocostat (ACC inhibitor); SEL, selonsertib (ASK1 inhibitor; SEL monotherapy arm [n=39] discontinued mid-trial).

* Observed case analysis assessed by a central pathologist according to the NASH Clinical Research Network (CRN) classification. All p-values (compared with placebo) were adjusted for presence of F4 and diabetes at baseline.

NASH resolution without worsening of fibrosis was uncommon in all treatment groups, including no placebo-treated patients and 4.5 percent of those treated with firsocostat and cilofexor (p=0.35).

Statistically significant improvements in multiple secondary endpoints were observed in patients treated with firsocostat and cilofexor compared with placebo, including a ≥2-point reduction in the NAFLD Activity Score (NAS) and ≥1-point reductions in steatosis, hepatocellular ballooning and lobular inflammation. Statistically significant improvements in noninvasive tests of fibrosis, liver injury and function, including ALT, AST, bilirubin and ELF score, were also observed in patients treated with this regimen compared with placebo.

Firsocostat, cilofexor and selonsertib, as monotherapies and dual combination regimens, were generally well tolerated. The most common adverse events in patients treated with the combination of firsocostat and cilofexor were mild to moderate pruritus (28.2 percent vs 15.4 percent with placebo; no discontinuations), headache, diarrhea and nausea. In patients treated with firsocostat and cilofexor, changes in lipid parameters were similar to those observed previously; 3.9 percent of patients experienced asymptomatic Grade 3 triglyceride elevations (>500 and <1000 mg/dL).

Further results from the ATLAS study will be presented at an upcoming scientific conference.

“NASH is a complex disease driven by multiple mechanisms. The results from the ATLAS study suggest the potential for a combination therapeutic approach for patients with advanced fibrosis by targeting different aspects of this disease,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “We continue to analyze the ATLAS data and will work with regulators to determine appropriate next steps for these therapies.”

“This trial provides novel data showing consistent improvements in liver histology and noninvasive tests, demonstrating the value of a combination approach to deliver meaningful changes in fibrosis, the key determinant of disease severity in NASH,” said Rohit Loomba, MD, MHSc, Director of NAFLD Research Center and Director of Hepatology, University of California, San Diego.

Cilofexor, firsocostat and selonsertib, alone or in combination, are investigational compounds and are not approved by the U.S. Food & Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established for these agents.

About Gilead’s Clinical Programs in NASH

NASH is a chronic and progressive liver disease characterized by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function. Individuals with advanced fibrosis, defined as bridging fibrosis (F3) or cirrhosis (F4), are at a significantly higher risk of liver-related and all-cause mortality.

Gilead is advancing multiple novel investigational compounds for the treatment of advanced fibrosis due to NASH, evaluating single-agent and combination therapy approaches against the core pathways associated with NASH – hepatocyte lipotoxicity, inflammation and fibrosis. Investigational compounds in development include the ACC inhibitor firsocostat, the selective, non-steroidal FXR agonist cilofexor, and the ASK1 inhibitor selonsertib. Gilead is also collaborating with Novo Nordisk A/S on a proof-of-concept study combining Gilead’s cilofexor and firsocostat and Novo Nordisk’s semaglutide (GLP-1 analogue) for the treatment of patients with NASH.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to complete its clinical trial programs for the treatment of advanced fibrosis due to NASH, including the evaluation of the investigational monotherapy and dual combination regimens of cilofexor, firsocostat and selonsertib, in the currently anticipated timelines or at all. In addition, there is the possibility of unfavorable results from ongoing and additional clinical trials involving these compounds. Further, it is possible that Gilead may make a strategic decision to discontinue development of these compounds if, for example, Gilead believes commercialization will be difficult relative to other opportunities in its pipeline. As a result, these compounds may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Greg Mann, Investors
(424) 322-1795

Arran Attridge, Media
(650) 425-8975

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Selected for German Lighting Brand Simprolux’s Human Centric Lighting23.9.2020 12:00:00 EESTPress release

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED technology, announced that its SunLike Series natural spectrum LEDs, which implement light that closely matches the spectrum of sunlight, has been adopted by German lighting brand Simprolux for its pendant luminaire “ORTUS”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005077/en/ Simprolux’s pendant luminaire “ORTUS” designed with SunLike Series natural spectrum LEDs (Photo: Business Wire) ORTUS is a premium product line that delivers residential lighting for dining table and study or work spaces, combining with Casambi Technologies Oy’s state-of-the-art automated wireless Bluetooth. With SunLike Series natural spectrum LEDs, the fixture are designed to bring out the natural color tones of objects achieving a lower blue light peak, similar to the sunlight spectral curve, which enables the reduction of scattered reflection and glare. It a

Arthur D. Little Announces New Board of Directors23.9.2020 11:00:00 EESTPress release

Following the completion of its ninth Partners’ and Shareholders’ Meeting since becoming a private partnership again in 2011, Arthur D. Little (ADL) today announces the new members of its Board of Directors. The Shareholders’ Meeting also re-elected Ignacio García Alves to serve a new tenure of three years as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005336/en/ Arthur D. Little Board of Directors (Photo: Business Wire) The results of the 2020 digital elections for the Board of Directors, with each member to serve a tenure of three years, were as follows: Ignacio García Alves (Chairman) Rodolfo Guzman Yusuke Harada Thomas Kuruvilla Bernd Schreiber Ulrica Sehlstedt Nick White. Held this year as a digital event that included over 100 participants, the Partners’ and Shareholders’ Meeting was an opportunity to celebrate the company’s ongoing success and resilience in the face of an exceptionall

ABP Publishing, a European Market Leader Audiobook Publisher, Rose Superior to Coronacrisis and Increased Sales 65%23.9.2020 11:00:00 EESTPress release

ABP Publishing shares the results of the second quarter. They show a significant rise in popularity and interest to audiobooks. Based on the financial reports for the second quarter, the sales increased 65% compared with the same period of the previous year. The most impressive results have been achieved in the French market with doubled sales. Noteworthy, during the quarantine, the structure of the listeners' interests has changed. For instance, the audiobooks in the category Relationships and parenting were bought by 50% more often than before the lockdown. The listeners who had to spend more time with their families were searching for ways of comfortable and mutually respected communication with their significant others. As judged by reviews, ABP Publishing audiobooks were immensely helpful in such an unusual situation. Speaking of listeners' reviews, the average merit of ABP Publishing audiobooks at Audible is more than 4.5 out of 5.0. Moreover, the number of users have completed l

Former HSBC Group COO Andy Maguire Joins Thought Machine as New Chair23.9.2020 11:00:00 EESTPress release

Thought Machine, the cloud native core banking technology company today announces the appointment of Andy Maguire as Chair. Maguire, former Group Chief Operating Officer of HSBC, joins Thought Machine effective immediately. At HSBC, Maguire led the bank’s IT, business operations, change support, procurement and real estate services. Prior to HSBC, Maguire was Boston Consulting Group’s managing partner for the UK and Ireland, and a member of their global executive committee. Maguire’s appointment comes at a time of significant momentum for Thought Machine, which recently closed its series B round at $125m, the fourth largest fundraising round in UK fintech this year. Furthermore, Thought Machine has added more than 150 employees in 2020 and has made a number of key senior hires in Q2 including Nicole Jude as Chief People Officer. Nicole recently led HR and people functions at Diligent Corporation and Bloomberg. The appointment of Maguire happens against the backdrop of banks around the

Servify Raises $23 Million in Series C, Led by Iron Pillar23.9.2020 10:45:00 EESTPress release

Servify , the device lifecycle management platform that integrates multiple OEM Brands and their sales and service ecosystem to deliver great after-sales service experience today announced that they have raised $23M in Series C financing. This round was led by its existing investor Iron Pillar, an India focused venture growth investor from its recently concluded Top Up Fund. In addition to all the existing investors such as Blume, Beenext and Tetrao SPF, this funding round also saw participation from funds managed by Global Alternatives Investor 57 Stars, multiple strategic investors like Sparkle Fund (an investment arm of DMI Finance), SF Roofdeck Capital LLC (Investment arm of Silicon Valley Investment Bank FT Partners), Go Ventures (investment arm of Go PLC, a Maltese integrated telecommunications company) and Madhu Kela Family Office. Servify’s existing Venture Debt provider Trifecta Capital also participated in the round. Sreevathsa Prabhakar, Founder, Servify said, “It is very sa

ARTIFICIAL INTELLIGENCE and CLOUD: The First Edition of the Second Level Master’s From Politecnico di Torino and Reply Will Begin in January 202123.9.2020 10:30:00 EESTPress release

Enrolment for the Politecnico di Torino Master’s in "Artificial Intelligence & Cloud: Hands-on Innovation", created by Reply, is now open. The unique educational programme has been developed to offer highly qualified students a professional specialization in the IT sector through its most innovative technologies: artificial intelligence and cloud. Starting in January 2021, the Master’s will last 12 months. Modules in the first semester - which will be taught on campus at Politecnico di Torino - will alternate between professors from Politecnico di Torino and Reply specialists, in a combination of theoretical lessons and development experiences. In the second semester students will carry out a 6-month work project at Reply, where they will be able to put into practice the knowledge acquired in the classroom by working within teams on live projects. The entire course is in English and open to international entrants. The first edition of the Master’s will be open to students with a Master

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom